Publications by authors named "Anthony Buisson"
Article Synopsis
- The PACIFIC study examined the presence of Adherent-Invasive E. coli (AIEC) in Crohn's disease patients from France and Hong Kong, finding similar prevalence rates (24.5% in France vs. 30.0% in Hong Kong).
- Antibiotic resistance was notably higher in AIEC strains from Hong Kong, particularly against multiple antibiotics, compared to those from France.
- All AIEC strains from both regions showed sensitivity to an EcoActive™ phage cocktail, indicating potential for this treatment to be effective globally against AIEC in Crohn's disease.
We investigated the role of ChiA and its associated polymorphisms in the interaction between Crohn's disease (CD)-associated adherent-invasive (AIEC) and intestinal mucosa. We observed a higher abundance of among the metagenome of CD patients compared to healthy subjects. In dextran sulfate sodium-induced colitis mice model, AIEC-LF82∆ colonization was reduced in ileal, colonic and fecal samples compared to wild-type LF82.
View Article and Find Full Text PDFHow to Incorporate Subcutaneous Infliximab and Vedolizumab in Your Practice.
Clin Gastroenterol Hepatol
October 2024
Background & Aims: Transmural healing (TH) is emerging as a potential Crohn's disease (CD) treatment target. Early biological treatment seems to be associated with improved disease outcomes, but its impact on TH remains unclear. We aimed to assess the impact of early biological treatment initiation on TH and its influence on CD prognosis.
View Article and Find Full Text PDFArticle Synopsis
- A study was conducted with 941 IBD patients to assess their satisfaction with different adalimumab preparations, including biosimilars and the original brand, Humira.
- The average satisfaction rating was 8.5 out of 10, with the highest satisfaction observed for Humira and its biosimilars like Hulio and Amgevita, where scores were notably above 8.5.
- Injection site reactions were reported by 31.8% of patients, and a portion of those previously treated with another adalimumab had discontinued due to side effects; overall, patient satisfaction remained high despite these issues.
Background: While fecal calprotectin (Fcal) is now recommended, the positioning of intestinal ultrasonography (IUS) is still unknown to monitor patients with CD.
Aims: To assess the agreement between IUS performed by a novice sonographer and Fcal to detect active CD and to compare these two monitoring tools to determine the need for therapeutic escalation.
Methods: In this cross-sectional prospective study, we consecutively included CD patients ≥ 18 years-old with concomitant IUS and Fcal testing within 7 days.
Background & Aims: Because transmural healing (TH) could be the best therapeutic target in Crohn's disease (CD), we aimed to build and validate a score to assess TH and transmural response (TR), and to confirm their association with favorable CD outcomes.
Methods: DEVISE-CD project encompassed 2 retrospective cohorts (274 and 224 patients with CD for development and validation phase, retrospectively) and 1 multicenter prospective validation cohort (N = 46 patients). A step-by-step process was used to build the modified Clermont score (C-score).
Introduction: Endoscopy is still the gold, standard for assessing disease activity in Crohn's disease (CD). Its invasiveness, poor acceptability, and cost limit its use in the era of tight control and treat-to-target management. Fecal calprotectin (FC) and intestinal ultrasound (IUS) are non-invasive alternatives to colonoscopy to assess disease activity.
View Article and Find Full Text PDFLong-term Outcome of Risankizumab in Crohn's Disease: a Real-world GETAID Study.
Clin Gastroenterol Hepatol
December 2024
Background & Aims: The aim of this study was to assess the long-term effectiveness and safety of risankizumab maintenance treatment in a large real-world cohort of patients with Crohn's Disease (CD).
Methods: From May 2021 to August 2023, all consecutive patients with CD treated with risankizumab in 25 GETAID centers have been retrospectively included. The primary endpoint was steroid-free clinical remission (Harvey Bradshaw Index [HBI] <5) at 52 weeks.
Background: Subcutaneous [SC] infliximab may provide multiple benefits over intravenous [IV] formulations. However, studies for efficacy and safety in inflammatory bowel disease [IBD] have been constrained by small sizes that limit the interpretation of outcomes, particularly for subgroups potentially at high risk of disease relapse.
Methods: We conducted a systematic review and random-effects meta-analysis up to January 2023, to evaluate the change in clinical remission after transitioning from IV to SC infliximab in patients with IBD in clinical remission.
Has the time come for a systematic top-down approach in Crohn's disease?
Lancet Gastroenterol Hepatol
May 2024
Background: Several studies have reported low levels of physical activity (PA) in patients with inflammatory bowel diseases (IBD), possibly related to a lack of information and support, despite the many recognized benefits such as cardiovascular prevention or quality of life (QoL) improvement.
Methods: The purpose of our study was to identify challenges faced by patients and to evaluate IBD impact on PA and QoL by using the International Physical Activity Questionnaire short form and the 32-item Inflammatory Bowel Disease Questionnaire (IBDQ-32) questionnaire, respectively. We also assessed the expectations and knowledge of patients and healthcare professionals using the MICI-Active questionnaire that we developed.
Article Synopsis
- - The study aimed to understand how often FGF23 levels are elevated in patients with hypophosphatemia and to explore the various underlying mechanisms of this condition.
- - Researchers conducted a study with 260 patients, measuring multiple blood markers, and found that 10.4% showed high FGF23 levels, indicating that at least 1 in 10 hypophosphatemia cases might be misclassified.
- - The elevated FGF23 cases were linked to several causes, including kidney issues and cancers, highlighting the need for routine FGF23 testing to improve treatment strategies for hypophosphatemia.
Background: While the efficacy of tofacitinib to induce and maintain clinical and endoscopic remission is well established in ulcerative colitis (UC), little is known about its efficacy to induce histological remission.
Methods: We conducted a retrospective multicentric cohort study. UC patients ≥ 16 years treated by tofacitinib in whom histological activity has been evaluated before and after induction were eligible.
Article Synopsis
- - The study evaluated the effectiveness of a nationwide anal cancer screening program for high-risk HIV patients in France, focusing on adherence to the program and cancer diagnosis rates.
- - Out of 700 patients, those with higher grades of anal intra-epithelial neoplasia (AIN) faced significantly increased risks of developing anal cancer, but strict adherence to screening (only 4.6% of participants) did not show a decrease in cancer risk.
- - Despite not diagnosing any anal cancer among adherent patients, the screening led to more frequent diagnoses of anal warts, indicating a need for further investigation into the program's actual impact on cancer risk reduction.
The REMSWITCH study recently demonstrated that switching from intravenous (IV) to subcutaneous (SC) infliximab (IFX) is feasible and well-accepted leading to a low risk of relapse in patients with inflammatory bowel disease (IBD). Because the doses of IV IFX depend on patients' weight contrary to SC IFX, whether the switch is also feasible in patients with IBD suffering from obesity remains questionable.
View Article and Find Full Text PDFBackground: Although ulcerative proctitis [UP] can dramatically impair quality of life, treatment efficacy has been poorly investigated in UP as it was historically excluded from phase 2/3 randomised controlled trials in ulcerative colitis. Our aim was to assess the effectiveness and safety of tofacitinib for the treatment of UP.
Methods: We conducted a retrospective, multicentre study in 17 GETAID centres, including consecutive patients with UP treated with tofacitinib.
Prevalence of and Factors Associated With Extraintestinal Manifestations and Their Remission in Inflammatory Bowel Disease: The EXTRA-Intestinal Manifestation Prospective Study From the Groupe d'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif.
Clin Transl Gastroenterol
December 2023
Introduction: Extraintestinal manifestations (EIMs) of inflammatory bowel disease (IBD) are challenging clinical situation. No prospective study assessed remission risk factors of EIMs. The aim of this study was to prospectively investigate the epidemiology, risk factors of EIM occurrence, and EIM remission in a large IBD cohort.
View Article and Find Full Text PDFBackground: In recent years, an increasing prevalence of obesity in inflammatory bowel disease (IBD) has been observed. However, only a few studies have focused on the impact of overweight and obesity on IBD-related disability.
Aims: To identify the factors associated with obese and overweight patients with IBD, including IBD-related disability.
Article Synopsis
- Fatigue is a common issue in patients with inflammatory bowel disease (IBD), with 54.1% experiencing fatigue and 37.1% reporting severe fatigue.
- Patients with active IBD experience significantly higher levels of fatigue compared to those with inactive disease.
- Key factors affecting fatigue include age, gender, sick leave, physical pain, emotional well-being, and sleep quality, suggesting that a holistic treatment approach is essential for managing IBD-related fatigue.
Article Synopsis
- The study investigates the effectiveness of adalimumab (ADA) in treating intra-abdominal abscesses in patients with Crohn's disease, specifically those who avoided surgery with prior successful abscess resolution.
- Conducted over two years with 117 eligible patients, the study found that 74% of participants achieved ADA success at 24 weeks, and 72.9% maintained success without relapse or the need for surgery at 104 weeks.
- Key factors linked to ADA failure included previous abscess drainage, longer disease duration, and inflammatory changes in mesenteric fat, highlighting the importance of proper abscess management before starting ADA treatment.
Introduction: There is debate over the impact of residual microscopic disease after ileocecal resection in Crohn's disease (CD) to predict recurrence. We conducted a meta-analysis to evaluate the impact of positive histological margins and plexitis after ileocecal resection on the risk of postoperative recurrence.
Methods: Using a systematic search, we identified.
Background: Whether healthcare workers with inflammatory bowel disease (IBD) are at increased risk of Novel coronavirus disease (COVID-19) due to occupational exposure is unknown.
Aim: To assess the risk of COVID-19 in healthcare workers with IBD.
Methods: A case control study enrolled 326 healthcare workers with IBD from 17 GETAID centres and matched non-healthcare workers with IBD controls (1:1) for gender, age, disease subtype and year of diagnosis.